Evidence map›Paper›PMID 37162929›Full record

ArticlebioRxiv : the preprint server for biology2023

Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.

Pan Ma, Jing Liu, Juan Qin, Lulu Lai, Gyu Seong Heo, Hannah Luehmann, Deborah Sultan, Andrea Bredemeyer, Geetika Bajapa, Guoshuai Feng and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Pan MaCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Jing LiuCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Juan QinDivision of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Lulu LaiDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Gyu Seong HeoMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Hannah LuehmannMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Deborah SultanMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Andrea BredemeyerCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Geetika BajapaCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Guoshuai FengCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Jesus JimenezCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Antanisha ParksCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Junedh AmruteCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Ana VillanuevaDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Yongjian LiuMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Chieh-Yu LinDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Matthias MackDepartment of Internal Medicine II - Nephrology, Universitatsklinikum Regensburg Klinik und Poliklinik Innere Medizin II, Regensburg, Bayern, Germany.
Kaushik AmancherlaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Javid MoslehiDivision of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Kory J LavineCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Washington University in St. Louis · USMallinckrodt (United States) · USUniversity of California, San Francisco · USUniversity Hospital Regensburg · DEVanderbilt University Medical Center · US

Funding

Training/DisseminationP41EB025815 · NIBIB · WASHINGTON UNIVERSITY · PI Robert J. Gropler · 2018 to 2026
$12.7M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6M
Targeted Molecular Probes for Atherosclerosis Imaging and TherapyR35HL145212 · NHLBI · WASHINGTON UNIVERSITY · PI LIU, YONGJIAN · 2019 to 2025
$5.1M
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9M
Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · PI Kory J. Lavine · 2022 to 2026
$4.3M
Molecular Imaging CCR2 Lung Inflammation and FibrosisR01HL151685 · NHLBI · WASHINGTON UNIVERSITY · PI BRODY, STEVEN · 2021 to 2025
$3.7M
PET Detection of CCR2 in Human AtherosclerosisR01HL150891 · NHLBI · WASHINGTON UNIVERSITY · PI GROPLER, ROBERT J., WOODARD, PAMELA K · 2020 to 2024
$3.7M
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapyR01HL160688 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jelena Levi, Youngho Seo · 2022 to 2026
$3.4M
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3M
Long-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3M
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic AneurysmsR01HL153436 · NHLBI · WASHINGTON UNIVERSITY · PI GROPLER, ROBERT J., ZAYED, MOHAMED A. · 2020 to 2023
$3.0M
The Role of Donor Innate Immune Responses in Regulating Alloimmunity after Heart TransplantationR01HL151078 · NHLBI · WASHINGTON UNIVERSITY · PI KREISEL, DANIEL, LAVINE, KORY J. · 2020 to 2023
$2.6M
NHLBI NIH HHS R01 HL131908NHLBI NIH HHS R01 HL138466NHLBI NIH HHS R01 HL139714NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL150891NHLBI NIH HHS R01 HL151078NHLBI NIH HHS R01 HL151685NHLBI NIH HHS R01 HL153436NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021NHLBI NIH HHS R01 HL160688NHLBI NIH HHS R35 HL145212NHLBI NIH HHS R35 HL161185NIAMS NIH HHS P30 AR073752NIBIB NIH HHS P41 EB025815NIH HHS S10 OD030403
6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1/PD-L1 or CTLA4 have revolutionized cancer management but are associated with devastating immune-related adverse events (irAEs) including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI-myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. While much has been learned regarding the role of T-cells in ICI-myocarditis, little is understood regarding the identity, transcriptional diversity, and functions of infiltrating macrophages. Methods: We employed an established murine ICI myocarditis model ( Results: We observed marked increases in CCR2 Conclusion: These data demonstrate that ICI-myocarditis is associated with the expansion of a specific population of IFN-γ induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.

Identifiers

PMID37162929
PMCPMC10168426
OpenAlexW4367395705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.